{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04319757",
            "orgStudyIdInfo": {
                "id": "ACE1702-001"
            },
            "organization": {
                "fullName": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
            "officialTitle": "A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "in-subjects-with-advanced-or-metastatic-expressing-solid-tumors"
        },
        "statusModule": {
            "statusVerifiedDate": "2023-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2020-05-19",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-03-18",
            "studyFirstSubmitQcDate": "2020-03-22",
            "studyFirstPostDateStruct": {
                "date": "2020-03-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-03-07",
            "lastUpdatePostDateStruct": {
                "date": "2023-03-08",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Acepodia Biotech, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "ACE1702 (anti-HER2 oNK cells) is an off-the-shelf Natural Killer (NK) cell product that targets human HER2-expressing solid tumors. The ACE1702-001 phase I study aims to evaluate the safety and tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing tumors, and to determine the phase Ib/II starting dose for ACE1702."
        },
        "conditionsModule": {
            "conditions": [
                "Locally Advanced Solid Tumor",
                "Metastatic Cancer",
                "Solid Tumor",
                "HER2-positive Gastric Cancer",
                "HER2-positive Metastatic Breast Cancer"
            ],
            "keywords": [
                "NK Cell Therapy",
                "Cellular Therapy",
                "Breast Cancer",
                "Gastric Cancer",
                "Ovarian Cancer",
                "Endometrial Cancer",
                "Metastatic Cancer",
                "Colorectal Cancer",
                "Head and Neck Cancer",
                "Pancreatic Cancer",
                "Bladder Cancer",
                "Non-small-cell Lung Carcinoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 36,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ACE1702 Dose Level 1",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 immunohistochemistry (IHC) 2+ or above.\n\nDose Level: 1 Planned number of subjects: 1 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "ACE1702 Dose Level 2",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.\n\nDose Level: 2 Planned number of subjects: 1 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "ACE1702 Dose Level 3",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.\n\nDose Level: 3 Planned number of subjects: 3 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "ACE1702 Dose Level 4",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.\n\nDose Level: 4 Planned number of subjects: 3 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "ACE1702 Dose Level 5",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.\n\nDose Level: 5 Planned number of subjects: 3 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                },
                {
                    "label": "ACE1702 Dose 6",
                    "type": "EXPERIMENTAL",
                    "description": "Lympho-conditioning agents followed by ACE1702 (anti-HER2 oNK cells) will be administered to patients with advanced or metastatic, HER2-expressing solid tumors. HER2 expressing is defined has having HER2 IHC 2+ or above.\n\nDose Level: 6 Planned number of subjects: 3 to 6",
                    "interventionNames": [
                        "Drug: ACE1702",
                        "Drug: Cyclophosphamide",
                        "Drug: Fludarabine"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ACE1702",
                    "description": "ACE1702 cellular therapy (anti-HER2 oNK cells) given intravenously",
                    "armGroupLabels": [
                        "ACE1702 Dose 6",
                        "ACE1702 Dose Level 1",
                        "ACE1702 Dose Level 2",
                        "ACE1702 Dose Level 3",
                        "ACE1702 Dose Level 4",
                        "ACE1702 Dose Level 5"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Cyclophosphamide",
                    "description": "Lympho-conditioning agent",
                    "armGroupLabels": [
                        "ACE1702 Dose 6",
                        "ACE1702 Dose Level 1",
                        "ACE1702 Dose Level 2",
                        "ACE1702 Dose Level 3",
                        "ACE1702 Dose Level 4",
                        "ACE1702 Dose Level 5"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Fludarabine",
                    "description": "Lympho-conditioning agent",
                    "armGroupLabels": [
                        "ACE1702 Dose 6",
                        "ACE1702 Dose Level 1",
                        "ACE1702 Dose Level 2",
                        "ACE1702 Dose Level 3",
                        "ACE1702 Dose Level 4",
                        "ACE1702 Dose Level 5"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Adverse events, including Dose Limiting Toxicities (DLTs) and Serious Adverse Events (SAEs)",
                    "description": "Number of subjects experiencing adverse events, and the frequency and severity of adverse events.\n\nEndpoint for determining the Maximum Tolerated Dose (MTD). If MTD is not identified, the highest dose administered becomes the Maximum Administered Dose (MAD).",
                    "timeFrame": "Day 7 through Day 28 / Day 4 through Day 25"
                },
                {
                    "measure": "Phase Ib/II starting dose for ACE1702",
                    "description": "The recommended phase Ib/II starting dose based on MTD. If MTD is not reached, then the recommended phase Ib/II dose will be determined based on the MAD, safety data, and pharmacodynamics data.",
                    "timeFrame": "Through study completion, up to 1 year"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Quantify NK cell persistence after administering ACE1702",
                    "description": "Duration of ACE1702 persistence",
                    "timeFrame": "Day 21"
                },
                {
                    "measure": "Evaluate immune function after administering ACE1702",
                    "description": "Measurement of serum cytokine levels, pg/mL (Interferon-\u03b3, TNF-\u03b1, IL-2, IL-6, IL-8 and IL-10) at set timepoints",
                    "timeFrame": "Day 21"
                }
            ],
            "otherOutcomes": [
                {
                    "measure": "Tumor response using Response Evaluation Criteria In Solid Tumors Assessment (RECIST) version 1.1",
                    "description": "Tumor response via radiographic assessments",
                    "timeFrame": "Day 35 (+7 day window) of each 6 week cycle, up to 24 months"
                },
                {
                    "measure": "Shift in serum tumor marker values (CA-125, CA 19-9, and CEA levels, in applicable tumor types)",
                    "description": "Tumor response via tumor marker assessments (in applicable tumor types)",
                    "timeFrame": "Day 35 (+7 day window) of each 6 week cycle, up to 24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Signed informed consent\n* Subjects must be \u2265 18 years of age ( \u2265 20 years of age for Taiwan site)\n* Subject with advanced or metastatic solid tumors that is not amenable to surgical resection and is not eligible or has refused other approved therapeutic options that have demonstrated clinical benefit.\n* Histologically confirmed HER2 expression.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status \u2264 1\n* Measurable or non-measurable evaluable disease according to RECIST 1.1\n* Adequate hematologic and end-organ function at baseline\n* Oxygen saturation via pulse oxygenation \u2265 90% at rest on room air\n\nExclusion Criteria:\n\n* Untreated central nervous system (CNS) metastases\n* Multiple primary malignancies\n* Clinically significant cardiovascular disease such as New York Heart Association (NYHA) cardiac disease (class III or greater)\n* Pregnant or lactating female\n* Serious, uncontrolled medical disorder that, in the opinion of the Investigator, would impair the ability of the subject to receive study treatment\n* History of autoimmune or immune mediated symptomatic disease\n* Any anti-cancer chemotherapy or targeted small molecule therapy, or experimental therapy/device within 4 weeks or 5 half-lives of the drug prior to planned start of the study",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Janet Pan, MPH",
                    "role": "CONTACT",
                    "phone": "+1-415-839-6787",
                    "email": "clinical@acepodiabio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Michael Kurman, MD",
                    "affiliation": "Acepodia Biotech, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Northwestern Univeristy",
                    "status": "COMPLETED",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60611",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "MD Anderson Cancer Center",
                    "status": "COMPLETED",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "Taipei Veteran General Hospital",
                    "status": "RECRUITING",
                    "city": "Taipei",
                    "country": "Taiwan",
                    "geoPoint": {
                        "lat": 25.04776,
                        "lon": 121.53185
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000013274",
                    "term": "Stomach Neoplasms"
                },
                {
                    "id": "D000009362",
                    "term": "Neoplasm Metastasis"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000013272",
                    "term": "Stomach Diseases"
                },
                {
                    "id": "D000009385",
                    "term": "Neoplastic Processes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M5546",
                    "name": "Carcinoma, Non-Small-Cell Lung",
                    "relevance": "LOW"
                },
                {
                    "id": "M5534",
                    "name": "Carcinoma",
                    "relevance": "LOW"
                },
                {
                    "id": "M5030",
                    "name": "Urinary Bladder Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M12974",
                    "name": "Ovarian Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M13110",
                    "name": "Pancreatic Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M11172",
                    "name": "Lung Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "asFound": "Gastric Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "asFound": "Metastatic Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9348",
                    "name": "Head and Neck Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M1704",
                    "name": "Carcinoma, Ovarian Epithelial",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M16062",
                    "name": "Stomach Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12330",
                    "name": "Neoplastic Processes",
                    "relevance": "LOW"
                },
                {
                    "id": "T4387",
                    "name": "Pancreatic Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4352",
                    "name": "Ovarian Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                },
                {
                    "id": "T4354",
                    "name": "Ovarian Epithelial Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC08",
                    "name": "Respiratory Tract (Lung and Bronchial) Diseases"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003520",
                    "term": "Cyclophosphamide"
                },
                {
                    "id": "C000024352",
                    "term": "Fludarabine"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018501",
                    "term": "Antirheumatic Agents"
                },
                {
                    "id": "D000018906",
                    "term": "Antineoplastic Agents, Alkylating"
                },
                {
                    "id": "D000000477",
                    "term": "Alkylating Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000019653",
                    "term": "Myeloablative Agonists"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "asFound": "Effect of",
                    "relevance": "HIGH"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "asFound": "Rate",
                    "relevance": "HIGH"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M20604",
                    "name": "Antirheumatic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20942",
                    "name": "Antineoplastic Agents, Alkylating",
                    "relevance": "LOW"
                },
                {
                    "id": "M3820",
                    "name": "Alkylating Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}